Skip to main content

Non-infectious Uveitis

Ophthalmology
5
Pipeline Programs
3
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
2
2
0
Early DiscoveryClinical DevelopmentMarket

Ophthalmology is a $3.7B market with a mature, consolidating portfolio dominated by glaucoma treatments and emerging corneal/retinal therapies.

$3.7B marketMature→ Stable30 products15 companies

Key Trends

  • Glaucoma therapeutics (prostaglandin analogs, adrenergic agents) represent 60%+ of spending but face patent cliffs 2028-2034
  • Innovative mechanisms (NGF agonists, LFA-1 antagonists, RTKIs) gaining traction in dry eye and retinal disease segments
  • Heavy trial activity (2,656 total) skewed toward Phase 4 (369) and Phase 3 (442), indicating mature clinical development landscape

Career Verdict

Ophthalmology offers stable mid-career opportunities with strong Commercial and Medical Affairs salaries, but limited innovation catalysts and significant patent cliff risk warrant careful timing of entry.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LUMIGANDeclining
$697M
AbbVie·LOE_APPROACHING
#2OXERVATEStable
$493M
Unspecified·PEAK
#3XIIDRAStable
$473M
Bausch + Lomb·PEAK7.6yr
#4INLYTAGrowing
$467M
Pfizer·PEAK11.2yr
#5HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING

Drug Class Breakdown

Prostaglandin Analogs (Bimatoprost)
$697M(19%)

mature, losing exclusivity

Nerve Growth Factor Agonists
$493M(13%)

peak growth in corneal disease

LFA-1 Antagonists (Dry Eye)
$473M(13%)

sustained peak sales

Receptor Tyrosine Kinase Inhibitors
$467M(13%)

expanding in retinal indications

Alpha-2 Adrenergic Agonists
$362M(10%)

mature, multiple LOE approaching

Combination Therapies (Brimonidine/Timolol)
$232M(6%)

mature, losing exclusivity

Complement Inhibitors
$223M(6%)

mature immunology approach

Career Outlook

Stable

Ophthalmology offers predictable mid-career growth with strong Commercial ($158K) and Medical Affairs ($247K) compensation but faces structural headwinds: patent cliffs 2028-2034 eliminate $97M in revenue, glaucoma franchise maturity limits blockbuster potential, and modest trial volume (2,656) signals incremental R&D expansion. Best suited for professionals seeking stable roles in established therapeutic areas rather than disruptive innovation.

Breaking In

Enter via Clinical Operations or Commercial analyst roles at CROs (Syneos 210 jobs) or large diagnostics players (Labcorp 904) to build domain expertise before targeting pharma MSL/Medical Affairs positions.

For Experienced Professionals

Experienced professionals should prioritize Medical Affairs and Market Access roles leveraging mature market knowledge; avoid product-specific expertise in glaucoma due to patent cliff concentration, and consider adjacent areas (retinal, corneal) where innovation catalysts remain.

In-Demand Skills

Glaucoma/dry eye clinical expertise and key opinion leader relationshipsRegulatory navigation for mature small-molecule formulations and device combinationsMarket access and reimbursement strategy (high generic/biosimilar pressure)

Best For

Medical Science Liaison (MSL) — strong $247K average salary, KOL interface criticalCommercial/Brand Manager — competitive $158K salaries, established product lifecycle managementClinical Operations Manager — high hiring volume (409 jobs), trial coordination in Phase 4-heavy pipeline

Hiring Landscape

$59K-$247K

Ophthalmology hiring (3,202 jobs) is distributed across diagnostics/devices (Labcorp 904, Abbott 348) and pharma commercial functions rather than concentrated in R&D. Top pharmaceutical employers (Pfizer 60, AstraZeneca 100, Regeneron 168) show modest pharma-specific headcount relative to market size, suggesting outsourced CRO and distributor dependency. Medical Affairs ($247K avg salary) commands premium compensation, signaling high barrier to entry but strong mid-career upside.

3,202
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

904Growing
348Stable
168Growing
219Stable

By Department

Clinical Operations(13%)
$150K
Commercial(10%)
$158K
Medical Affairs(3%)
$247K
R&D(6%)
$145K
Engineering(9%)
$112K

Clinical Operations and Commercial roles offer entry-level stability ($150K-$158K); Medical Affairs commands premium salaries ($247K) but requires advanced credentials; limited R&D hiring (207 jobs) suggests constrained innovation investment.

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
2
AIN457Phase 31 trial
AIN457Phase 31 trial
AIN457Phase 21 trial
Active Trials
NCT00685399Completed76Est. Sep 2013
NCT01032915Terminated125Est. Jun 2011
NCT01090310Terminated86Est. Jul 2011
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
2
Fluocinolone Acetonide 0.59mgPhase 2/31 trial
fluocinolone acetonide intravitreal implantPhase 2/31 trial
Active Trials
NCT00456482Terminated239Est. Apr 2006
NCT00468871Completed140Est. Jun 2006
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
dexamethasone intravitreal implantN/A1 trial
Active Trials
NCT02951975Terminated246Est. Dec 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozAIN457
SandozAIN457
Bausch HealthFluocinolone Acetonide 0.59mg
Bausch Healthfluocinolone acetonide intravitreal implant
SandozAIN457
AbbViedexamethasone intravitreal implant

Clinical Trials (6)

Total enrollment: 912 patients across 6 trials

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Start: Aug 2010Est. completion: Jul 201186 patients
Phase 3Terminated

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Start: Feb 2010Est. completion: Jun 2011125 patients
Phase 3Terminated
NCT00456482Bausch HealthFluocinolone Acetonide 0.59mg

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant

Start: May 2002Est. completion: Apr 2006239 patients
Phase 2/3Terminated
NCT00468871Bausch Healthfluocinolone acetonide intravitreal implant

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy

Start: Apr 2002Est. completion: Jun 2006140 patients
Phase 2/3Completed

Safety and Efficacy of AIN457 in Noninfectious Uveitis

Start: Jun 2008Est. completion: Sep 201376 patients
Phase 2Completed
NCT02951975AbbViedexamethasone intravitreal implant

Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Start: Jan 2017Est. completion: Dec 2018246 patients
N/ATerminated

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.